Table 2. Baseline laboratory factors by DPP4a quartiles and their correlations with DPP4a.
| U/L | Total | Q1 | Q2 | Q3 | Q4 | P | Correlation |
|
|---|---|---|---|---|---|---|---|---|
| ≤21.53 | 21.54–27.14 | 27.15–32.92 | ≥32.96 | r | p | |||
| Lipid profile | ||||||||
| Total cholesterol (mg/dL) | 4.11 ± 1.04 | 3.97 ± 1.03 | 4.06 ± 1.03 | 4.07 ± 1.08 | 4.32 ± 1.01 | 0.01 | 0.13a | <0.01 |
| Triglyceride (mg/dL) | 1.56 ± 0.84 | 1.53 ± 0.71 | 1.55 ± 0.78 | 1.45 ± 0.78 | 1.68 ± 0.85 | 0.07 | 0.06a | 0.11 |
| HDL cholesterol (mg/dL) | 1.05 ± 0.29 | 1.01 ± 0.28 | 1.03 ± 0.28 | 1.07 ± 0.29 | 1.09 ± 0.31 | 0.06 | 0.11a | 0.01 |
| LDL cholesterol (mg/dL) | 2.53 ± 0.89 | 2.42 ± 0.85 | 2.50 ± 0.85 | 2.53 ± 0.86 | 2.67 ± 0.86 | 0.03 | 0.11a | <0.01 |
| Coagulation profile | ||||||||
| Thrombin time (sec) | 16.60 (15.80–18.53) | 16.30 (15.60–17.80) | 16.70 (15.80–18.20) | 16.70 (15.90–19.63) | 16.90 (16.20–19.48) | <0.01 | 0.16b | <0.01 |
| Prothrombin time (sec) | 13.64 ± 1.40 | 13.74 ± 1.41 | 13.62 ± 1.23 | 13.66 ± 1.08 | 13.55 ± 1.80 | 0.67 | −0.01a | 0.83 |
| APTT (sec) | 37.85 (34.90–43.33) | 38.10 (34.10–41.90) | 38.00 (35.28–43.65) | 38.05 (35.30–44.43) | 37.60 (35.10–42.55) | 0.79 | 0.02b | 0.76 |
| Fibrinogen (g/L) | 3.75 ± 1.16 | 4.07 ± 1.35 | 3.91 ± 1.22 | 3.58 ± 1.01 | 3.45 ± 0.94 | <0.01 | −0.21a | <0.01 |
| FPB (mmol/l) | 6.97 ± 2.71 | 7.21 ± 2.86 | 7.00 ± 2.72 | 6.94 ± 2.90 | 6.72 ± 2.28 | 0.53 | −0.05a | 0.20 |
| HbA1C (%)* | 6.40 ± 1.38 | 6.61 ± 1.62 | 6.20 ± 1.16 | 6.49 ± 1.47 | 6.26 ± 1.14 | 0.13 | −0.06a | 0.27 |
| peak CK-MB (ng/mL) | 6.83 (1.83–131.76) | 4.52 (1.74–76.99) | 7.42 (1.86–162.03) | 8.85 (1.88–154.60) | 9.85 (1.82–215.43) | 0.11 | 0.10b | 0.01 |
| peak cTNT (ng/mL) | 0.65 (0.45–4.22) | 0.62 (0.05–3.21) | 0.53 (0.06–3.95) | 0.56 (0.30–4.70) | 1.08 (0.50–5.26) | 0.64 | 0.05b | 0.19 |
| peak myoglobin (ng/mL) | 49.84 (28.43–384.70) | 44.19 (28.03–191.68) | 38.09 (29.20–356.58) | 49.84 (28.34–618.10) | 127.60 (28.00–691.60) | 0.12 | 0.14b | <0.01 |
| pro-BNP (pg/mL) | 653.90 (250.00–1581.00) | 855.70 (250.15–1960.50) | 659.20 (241.10–1486.00) | 687.90 (282.70–1611.00) | 553.70 (234.23–1396.00) | 0.21 | −0.07b | 0.06 |
| Creatinine (umol/L) | 78.30 (68.20–90.18) | 79.70 (65.30–95.80) | 79.90 (66.45–91.75) | 78.50 (70.28–91.65) | 76.35 (67.45–85.50) | 0.09 | −0.07b | 0.049 |
| GGT (U/L) | 32.80 (21.70–53.90) | 30.40 (21.33–45.78) | 30.60 (21.20–54.30) | 31.00 (22.60–48.95) | 38.00 (23.60–73.10) | <0.01 | 0.14b | <0.01 |
APTT, activated partial thromboplastin time; BNP, brain natriuretic peptide; CK-MB, MB isoenzyme of creatine kinase; cTNT, cardiac troponin T; DPP4a, plasma dipeptidyl peptidase-4 activity; FPG, fasting plasma glucose; GGT, gamma-glutamyltransferase; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; LDL, low-density lipoprotein;
aPearson correlation coefficients; bSpearman correlation coefficients.
*HbA1c was only detected in 373 patients; Number of patients detected were 107 in Q1, 88 in Q2, 88 in Q3 and 89 in Q4.